Individuals with LAAT had a significantly greater left atrial diameter than patients without LAAT and were more likely to have previous stroke/TIA/systemic thromboembolism with a significantly lower angiotensin II receptor blocker or angiotensin-converting-enzyme inhibitor treatment rate. This evidence concerns the gene ACE and stroke disorder.